Impact of fluoroquinolone use on multidrug-resistant bacteria emergence

被引:10
作者
Nseir, S
Ader, F
Marquette, CH
Durocher, A
机构
[1] Ctr Hosp Reg & Univ Lille, Serv Reanimat Med, Hop A Calmette, F-59037 Lille, France
[2] Univ Lille 2, EA 3614, Lab Evaluat Med, F-59000 Lille, France
[3] Hop G Chatiliez, Serv Reanim Med & Malad Infect, F-59208 Tourcoing, France
[4] CHU Lille, Hop A Calmette, Clin Malad Resp, F-59037 Lille, France
来源
PATHOLOGIE BIOLOGIE | 2005年 / 53卷 / 8-9期
关键词
fluoroquinolones; bacterial resistance; multidrug-resistant bacteria; antibiotic treatment;
D O I
10.1016/j.patbio.2005.07.008
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
During the last two decades, fluoroquinolone use has significantly increased in Europe and in the USA. This could be explained by the arrival of newer fluoroquinolones with antipneumoccal activity. Increased use of fluoroquinolones is associated with higher rates of bacterial resistance to these antibiotics. Resistance of Gram-negative bacilli to fluoroquinolones is increasing in industrialized countries. In addition, fluoroquinolone use has been identified as a risk factor for colonization and infection to methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumanni, extending-spectrum beta-lactamase producing Gram negative bacilli, and multidrug-resistant bacteria. Nosocomial infections due to multidrug-resistant bacteria are associated with higher mortality and morbidity rates. This could be related to more frequent inappropriate initial antibiotic treatment in these patients. Limiting the use of fluoroquinolones, limiting the duration of treatment with fluoroquinolones, and using appropriate dosage of these antibiotics could be suggested to reduce resistance to these antibiotics and to reduce the emergence of multidrug-resistant bacteria. (c) 2005 Elsevier SAS. All rights reserved.
引用
收藏
页码:470 / 475
页数:6
相关论文
共 55 条
[21]   Clinical epidemiology of ciprofloxacin resistance and its relationship to broad-spectrum cephalosporin resistance in bloodstream infections caused by Enterobacter species [J].
Kang, CI ;
Kim, SH ;
Park, WB ;
Lee, KD ;
Kim, HB ;
Kim, EC ;
Oh, MD ;
Choe, KW .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2005, 26 (01) :88-92
[22]   Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. [J].
Kaye, KS ;
Cosgrove, S ;
Harris, A ;
Eliopoulos, GM ;
Carmeli, Y .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) :2628-2630
[23]   Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002 [J].
Kern, WV ;
Steib-Bauert, M ;
de With, K ;
Reuter, S ;
Bertz, H ;
Frank, U ;
von Baum, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (01) :57-60
[24]  
KOLLEF MH, 2005, IN PRESS CRIT CARE
[25]   Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections [J].
Lautcnbach, E ;
Fishman, NO ;
Bilker, WB ;
Castiglioni, A ;
Metlay, JP ;
Edelstein, PH ;
Strom, BL .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (21) :2469-2477
[26]   Longitudinal trends in fluoroquinolone resistance among enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: Differences in the emergence and epidemiology of resistance across organisms [J].
Lautenbach, E ;
Strom, BL ;
Nachamkin, I ;
Bilker, WB ;
Marr, AM ;
Larosa, LA ;
Fishman, NO .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (05) :655-662
[27]   Fluproquinolone utilization, in the emergency departments of academic medical centers - Prevalence of, and risk factors for, inappropriate use [J].
Lautenbach, E ;
Larosa, LA ;
Kasbekar, N ;
Peng, HP ;
Maniglia, RJ ;
Fishman, NO .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (05) :601-605
[28]   Fluoroquinolone prescribing in the United States: 1995 to 2002 [J].
Linder, JA ;
Huang, ES ;
Steinman, MA ;
Gonzales, R ;
Stafford, RS .
AMERICAN JOURNAL OF MEDICINE, 2005, 118 (03) :259-268
[29]   Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999 [J].
Livermore, DM ;
James, D ;
Reacher, M ;
Graham, C ;
Nichols, T ;
Stephens, P ;
Johnson, AP ;
George, RC .
EMERGING INFECTIOUS DISEASES, 2002, 8 (05) :473-478
[30]   Risk factors for resistance to antimicrobial agents among nursing home residents [J].
Loeb, MB ;
Craven, S ;
McGeer, AJ ;
Simor, AE ;
Bradley, SF ;
Low, DE ;
Armstrong-Evans, M ;
Moss, LA ;
Walter, SD .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2003, 157 (01) :40-47